SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-22-036744
Filing Date
2022-10-11
Accepted
2022-10-11 08:30:19
Documents
15
Period of Report
2022-10-11
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10042808_8k.htm   iXBRL 8-K 36111
2 EXHIBIT 3.1 brhc10042808_ex3-1.htm EX-3.1 7358
3 EXHIBIT 3.2 brhc10042808_ex3-2.htm EX-3.2 126930
4 EXHIBIT 3.3 brhc10042808_ex3-3.htm EX-3.3 10670
  Complete submission text file 0001140361-22-036744.txt   354572

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA btx-20221011.xsd EX-101.SCH 3872
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE btx-20221011_lab.xml EX-101.LAB 23292
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btx-20221011_pre.xml EX-101.PRE 16558
9 EXTRACTED XBRL INSTANCE DOCUMENT brhc10042808_8k_htm.xml XML 4406
Mailing Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220
Business Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220 (212) 582-1199
Brooklyn ImmunoTherapeutics, Inc. (Filer) CIK: 0000748592 (see all company filings)

IRS No.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 221302448
SIC: 2834 Pharmaceutical Preparations